Followers | 179 |
Posts | 24830 |
Boards Moderated | 17 |
Alias Born | 04/03/2002 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 11, 2021 2:02:02 PM
https://www.gaintherapeutics.com/about/overview.html
LEADING THE DISCOVERY
of Allosteric Binding Sites to Create New Medicines
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform.
By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders.
Protein misfolding is an underlying biological issue of many diseases, including lysosomal storage disorders and some neurodegenerative diseases such as Parkinson’s disease. When a protein misfolds, its 3D structure is disrupted and it can no longer function properly. While some treatments are available for these types of disorders, they have significant limitations.
Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
Recent GANX News
- Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 • GlobeNewswire Inc. • 06/28/2024 08:39:04 PM
- Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO • GlobeNewswire Inc. • 06/27/2024 08:08:08 PM
- Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease • GlobeNewswire Inc. • 06/27/2024 12:35:48 PM
- Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/25/2024 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 12:30:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:40:23 PM
- Gain Therapeutics Announces Pricing of $11.0 Million Public Offering • GlobeNewswire Inc. • 06/14/2024 01:00:59 AM
- Gain Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 06/13/2024 08:44:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/13/2024 08:38:54 PM
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:06:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:03:12 PM
- Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 04/24/2024 01:25:00 PM
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer • GlobeNewswire Inc. • 04/08/2024 01:25:00 PM
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 04/01/2024 01:25:00 PM
- Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Gain Therapeutics to Present at Public Ventures Discovery Day • GlobeNewswire Inc. • 03/15/2024 06:30:11 PM
- Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 02/27/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:17 PM
- Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight • GlobeNewswire Inc. • 02/14/2024 05:29:34 PM
- UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 02:56:04 PM
- Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:26:33 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM